Disease modifying drugs for rheumatological diseases: a brief history of everything

被引:6
|
作者
Giles, Joanna L. [1 ]
Polak, Oktawia J. [1 ]
Landon, John [1 ]
机构
[1] MicroPharm Ltd, Newcastle Emlyn, Carmarthenshire, Australia
来源
INFLAMMATORY DISORDERS - PT B | 2020年 / 120卷
关键词
TUMOR-NECROSIS-FACTOR; JUVENILE IDIOPATHIC ARTHRITIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; ACTIVE PSORIATIC-ARTHRITIS; B-CELL DEPLETION; FREE H CHAINS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; SYNOVIAL-FLUID; FACTOR-ALPHA;
D O I
10.1016/bs.apcsb.2019.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The rheumatological diseases are a group of chronic, painful, degenerative and debilitating conditions with an increasing prevalence across the globe. The pathogenesis of these disorders is complex, overlapping and not fully understood. As such, it is difficult and time consuming to achieve correct diagnosis and complete remission for an individual patient. In this review we describe the most common forms of inflammatory arthritis and discuss how the management and treatment options for these rheumatic diseases have developed over time. We outline the successes and the limitations of current treatment regimens and discuss the economic burden of the current options. With advancements in understanding of disease mechanisms, we discuss the importance of the biologics revolution in the context of rheumatological disease and how the development of biosimilars and small molecule inhibitors will impact current treatment options in order to alleviate some of the cost burden of biological therapies. The ideal treatment strategy for the future would involve personalized and predictive medicine where by treatments can be tailored to an individual patient's needs in order to achieve fast and successful remission with no adverse events.
引用
收藏
页码:313 / 348
页数:36
相关论文
共 50 条
  • [21] Disease-Modifying Antirheumatic Drugs
    Brasington, Richard
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2009, 34A (02): : 347 - 348
  • [22] Disease-modifying antirheumatic drugs
    Lambert, David G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2009, 10 (01): : 35 - 37
  • [23] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    STECHER, VJ
    CARLSON, JA
    CONNOLLY, KM
    BAILEY, DM
    MEDICINAL RESEARCH REVIEWS, 1985, 5 (03) : 371 - 390
  • [24] Disease-modifying antirheumatic drugs
    Slack, S
    Furst, DE
    DRUGS OF TODAY, 1996, 32 (06) : 463 - 476
  • [25] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    SMITH, MD
    AHERN, MJ
    MEDICAL JOURNAL OF AUSTRALIA, 1992, 157 (11-12) : 797 - 801
  • [26] Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer
    Kleinert, S.
    Waldner, M.
    Wendler, J.
    Kunzmann, V.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2016, 75 (01): : 41 - 46
  • [27] UTILIZATION PATTERNS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES
    Anghel, Laura-Alexandra
    Leucuta, Daniel-Corneliu
    Farcas, Andreea Maria
    Oprean, Radu Nicolae
    FARMACIA, 2019, 67 (01) : 184 - 192
  • [28] ASSOCIATION BETWEEN DISEASE MODIFYING ANTIRHEUMATIC DRUGS AND HEART FAILURE IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES
    Zagouras, Alexia
    Chatterjee, Soumya
    Tang, Wai Hong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 880 - 880
  • [29] A BRIEF-HISTORY OF THE RHEUMATIC DISEASES
    BENEDEK, TG
    RODNAN, GP
    BULLETIN ON THE RHEUMATIC DISEASES, 1982, 32 (06) : 59 - 68
  • [30] Disease-modifying drugs and Parkinson's disease
    Allain, Herve
    Bentue-Ferrer, Daniele
    Akwa, Yvette
    PROGRESS IN NEUROBIOLOGY, 2008, 84 (01) : 25 - 39